Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells

Cancer Science

Volumn 104, Issue 9, 2013, Pages 1178-1188

  Li, Gui Dong ^a,b   Kawashima, Hiroyuki ^a   Ogose, Akira ^a   Ariizumi, Takashi ^a   Hotta, Tetsuo ^a   Kuwano, Ryozo ^c   Urata, Yasuo ^d   Fujiwara, Toshiyoshi ^e,f   Endo, Naoto ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c NIIGATA UNIVERSITY   (Japan)

^d National Institute of Infectious Diseases   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; ADENOSINE TRIPHOSPHATE; APOPTOSIS INHIBITOR; ONCOLYTIC ADENOVIRUS; TELOMELYSIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CELL DEATH; CELL VIABILITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROTEIN DEPLETION; SOFT TISSUE SARCOMA;

ADENINE; ADENOSINE TRIPHOSPHATE; ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; HEK293 CELLS; HELA CELLS; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SARCOMA; TELOMERASE;

EID: 84883461573     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12208     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012; 62: 10-29.
2. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005; 353: 701-11.
3. Matushansky I, Taub RN. Adjuvant chemotherapy in 2011 for patients with soft-tissue sarcoma. Nat Rev Clin Oncol 2011; 8: 434-8.
4. Patrikidou A, Domont J, Cioffi A, Le Cesne A. Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol 2011; 12: 21-31.
5. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol 2002; 3: 17-26.
6. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002; 2: 938-50.
7. Nemunaitis J, Khuri F, Ganly I et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-98.
8. Reid T, Galanis E, Abbruzzese J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2001; 62: 6070-9.
9. Hamid O, Varterasian ML, Wadler S et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-504.
10. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5.
11. Li G, Kawashima H, Ogose A et al. Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus. J Cancer Res Clin Oncol 2011; 137: 1037-51.
12. Wirth T, Zender L., Schulte B. et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003; 63: 3181-8.
13. Nemunaitis J, Tong AW, Nemunaitis M et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010; 18: 429-34.
14. Umeoka T, Kawashima T, Kagawa S et al. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 2004; 64: 6259-65.
15. Fujiwara T, Kagawa S, Kishimoto H et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer 2006; 119: 432-40.
16. Kishimoto H, Kojima T, Watanabe Y et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 2006; 12: 1213-9.
17. Kawashima T, Kagawa S, Kobayashi N et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10: 285-92.
18. Watanabe T, Hioki M, Fujiwara T et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 2006; 312: 256-65.
19. Hashimoto Y, Watanabe Y, Shirakiya Y et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 2008; 99: 385-90.
20. Takakura M, Nakamura M, Kyo S et al. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther 2010; 17: 11-9.
21. Gu W, Ogose A, Kawashima H et al. High-level expression of the coxsackievirus and adenovirus receptor messenger RNA in osteosarcoma, Ewing's sarcoma, and benign neurogenic tumors among musculoskeletal tumors. Clin Cancer Res 2004; 10: 3831-8.
22. Bergelson JM, Cunningham JA, Droguett G et al. Finberg, Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-3.
23. Wuchter C, Ruppert V, Schrappe M, Dörken B, Ludwig WD, Karawajew L. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood 2002; 99: 4109-15.
24. Wang SM, Wu R. The double danger of ethanol and hypoxia: their effects on a hepatoma cell line. Int J Clin Exp Pathol 2009; 2: 182-9.
25. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 1994; 269: 30761-4.
26. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998; 273: 33533-9.
27. Vergne I, Roberts E, Elmaoued RA et al. Deretic, Control of autophagy initiation by phosphoinositide 3-phosphatase Jumpy. EMBO J 2009; 28: 2244-58.
28. Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. J Pathol 2010; 221: 117-24.
29. Kabeya Y, Mizushima M, Ueno T et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19: 5720-8.
30. Bell SE, Quinn DM, Kellett GL, Warr JR. 2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis. Br J Cancer 1998; 78: 1464-70.
31. Koyama AH, Irie H, Ueno F, Ogawa M, Nomoto A, Adachi A. Suppression of apoptotic and necrotic cell death by poliovirus. J Gen Virol 2001; 82: 2965-72.
32. Los M, Mozoluk M, Ferrari D et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell 2002; 13: 978-88.
33. Hamahata K, Adachi S, Matsubara H et al. Mitochondrial dysfunction is related to necrosis-like programmed cell death induced by A23187 in CEM cells. Eur J Pharmacol 2005; 516: 187-96.
34. Richter C, Schweizer M, Cossarizza A, Franceschi C. Control of apoptosis by the cellular ATP level. FEBS Lett 1996; 378: 107-10.
35. Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997; 185: 1481-6.
36. van der Toorn M, Slebos DJ, de Bruin HG et al. Cigarette smoke-induced blockade of the mitochondrial respiratory chain switches lung epithelial cell apoptosis into necrosis. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1211-8.
37. Takakura M, Kyo S, Kanya T et al. Cloning of human telomerase catalytic subunit (hTERT) gene for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551-7.
38. Begelson JM. Receptors mediating adenovirus attachment and internalization. Biochem Pharmacol 1999; 57: 975-9.
39. Patel RM, Folpe AL. Immunohistochemistry for human telomerase reverse transcriptase catalytic subunit (hTERT): a study of 143 benign and malignant soft tissue and bone tumours. Pathology 2009; 41: 527-32.
40. Taki M, Kagawa S, Nishizaki M et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005; 24: 3130-40.
41. Yokoyama T, Iwado E, Kondo Y et al. Autophagy-inducing agents augment the antitumor effect of telomerase-selective oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther 2008; 15: 1233-9.
42. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009; 43: 67-93.
43. Berry DL, Baehrecke DH. Autophagy functions in programmed cell death. Autophagy 2008; 4: 359-60.
44. Amaravadi RK, Yu D, Lum JJ et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117: 326-36.
45. Nakamura O, Hitora T, Akisue T, Kawamoto T, Yamagami Y, Yamamoto T. Inhibition of induced autophagy increases apoptosis of Nara-H cells. Int J Oncol 2011; 39: 1545-52.
46. Chiou SK, White E. Inhibition of ICE-like proteases inhibits apoptosis and increases virus production during adenovirus infection. Virology 1998; 244: 108-18.
47. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
48. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-42.